CL2021002111A1 - Composición para vacuna viva atenuada contra la influenza y proceso para su preparación. - Google Patents

Composición para vacuna viva atenuada contra la influenza y proceso para su preparación.

Info

Publication number
CL2021002111A1
CL2021002111A1 CL2021002111A CL2021002111A CL2021002111A1 CL 2021002111 A1 CL2021002111 A1 CL 2021002111A1 CL 2021002111 A CL2021002111 A CL 2021002111A CL 2021002111 A CL2021002111 A CL 2021002111A CL 2021002111 A1 CL2021002111 A1 CL 2021002111A1
Authority
CL
Chile
Prior art keywords
laiv
strains
live attenuated
composition
devoid
Prior art date
Application number
CL2021002111A
Other languages
English (en)
Inventor
Rajeev Mhalasakant Dhere
Leena Ravindra Yeolekar
Milan Shomenath Ganguly
Parikshit Dharampal Tyagi
Umesh Gorakh Sagar
Swapnil Prabhakar Narale
Yashodhan Dilip Anaspure
Sham Ramdas Tupe
Original Assignee
Serum Inst Of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Inst Of India Pvt Ltd filed Critical Serum Inst Of India Pvt Ltd
Publication of CL2021002111A1 publication Critical patent/CL2021002111A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente divulgación proporciona composiciones y métodos para la fabricación y obtención de una composición para una vacuna viva atenuada contra la influenza (LAIV) que se puede administrar por vía intranasal para proporcionar protección contra la infección por el virus de la influenza. Dichas cepas de LAIV se basan en fenotipos adaptados al frío, sensibles a la temperatura y atenuados de virus donantes maestros (MGV) que contienen los genes de glicoproteínas superficiales de las cepas de influenza estacional o pandemia de tipo salvaje. Además, dichas cepas de LAIV están más adaptadas para crecer en células MDCK (células renales caninas Madin Darby). El uso de huevos se evita en la fabricación de vacunas a gran escala. El proceso de purificación está desprovisto de pasos de cromatografía. Dicha composición de LAIV incluye uno o más virus vivos atenuados de la vacuna contra la influenza y está desprovista de polímeros y tensioactivos.
CL2021002111A 2019-02-15 2021-08-11 Composición para vacuna viva atenuada contra la influenza y proceso para su preparación. CL2021002111A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201921006071 2019-02-15

Publications (1)

Publication Number Publication Date
CL2021002111A1 true CL2021002111A1 (es) 2022-01-28

Family

ID=69740470

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002111A CL2021002111A1 (es) 2019-02-15 2021-08-11 Composición para vacuna viva atenuada contra la influenza y proceso para su preparación.

Country Status (20)

Country Link
US (1) US20220211837A1 (es)
EP (1) EP3924052A1 (es)
JP (1) JP2022520443A (es)
KR (1) KR20210129073A (es)
CN (1) CN113646047A (es)
AR (1) AR119691A1 (es)
AU (1) AU2020222113A1 (es)
BR (1) BR112021016059A2 (es)
CA (1) CA3130036A1 (es)
CL (1) CL2021002111A1 (es)
CO (1) CO2021010751A2 (es)
IL (1) IL285526A (es)
JO (1) JOP20200037A1 (es)
MA (1) MA54942A (es)
MX (1) MX2021009837A (es)
PE (1) PE20212322A1 (es)
SG (1) SG11202108766RA (es)
TW (1) TW202045205A (es)
UY (1) UY38587A (es)
WO (1) WO2020165912A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR025750A1 (es) * 1999-09-24 2002-12-11 Smithkline Beecham Biolog Vacunas
RU2547587C2 (ru) * 2008-09-24 2015-04-10 Медиммун, Ллк Способы культивирования клеток, размножения и очистки вирусов
TWI670085B (zh) * 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
JP7198264B2 (ja) * 2017-07-11 2022-12-28 ユニバーサル スタビリゼイション テクノロジーズ，インコーポレイテッド バイオ医薬品を保存するための方法

Also Published As

Publication number Publication date
AU2020222113A1 (en) 2021-10-07
SG11202108766RA (en) 2021-09-29
TW202045205A (zh) 2020-12-16
JP2022520443A (ja) 2022-03-30
EP3924052A1 (en) 2021-12-22
CO2021010751A2 (es) 2021-09-09
CA3130036A1 (en) 2020-08-20
MA54942A (fr) 2021-12-22
CN113646047A (zh) 2021-11-12
UY38587A (es) 2020-09-30
PE20212322A1 (es) 2021-12-14
IL285526A (en) 2021-09-30
JOP20200037A1 (ar) 2020-08-15
BR112021016059A2 (pt) 2021-10-13
AR119691A1 (es) 2022-01-05
MX2021009837A (es) 2021-09-10
US20220211837A1 (en) 2022-07-07
WO2020165912A1 (en) 2020-08-20
KR20210129073A (ko) 2021-10-27

Similar Documents

Publication Publication Date Title
Easterbrook et al. Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice
BARBERIS et al. History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines
Wong et al. Traditional and new influenza vaccines
Shi et al. Origin and molecular characterization of the human-infecting H6N1 influenza virus in Taiwan
MX2010003202A (es) Metodo para producir virus de la gripe.
Becker et al. Influenza vaccines: successes and continuing challenges
BR112012020839A2 (pt) vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
AR069883A1 (es) Virus de la estomatitis vesicular geneticamente modificado, composicion inmunogenica que lo comprende, metodo para producirlo, metodos para adaptar un virus para crecer en el cultivo de cedula y para proteger un mamifero contra la infeccion con un organismo patogeno
Isakova-Sivak et al. Broadly protective anti-hemagglutinin stalk antibodies induced by live attenuated influenza vaccine expressing chimeric hemagglutinin
UY37179A (es) Composiciones producidas por microorganismos con actividad estimuladora sobre las plantas
Ren et al. H5N1 influenza virus-like particle vaccine protects mice from heterologous virus challenge better than whole inactivated virus
NZ739260A (en) Inactivated canine influenza vaccines and methods of making and uses thereof
AR115069A1 (es) Virus vacuna quimérico sintético
Wohlbold et al. An H10N8 influenza virus vaccine strain and mouse challenge model based on the human isolate A/Jiangxi-Donghu/346/13
Nishi et al. Genetic analysis of an H5N2 highly pathogenic avian influenza virus isolated from a chicken in a live bird market in Northern Vietnam in 2012
CL2021002111A1 (es) Composición para vacuna viva atenuada contra la influenza y proceso para su preparación.
ŠANTAK Old and new ways to combat human influenza virus
Zhou et al. High-yield production of a stable Vero cell-based vaccine candidate against the highly pathogenic avian influenza virus H5N1
US20220160863A1 (en) High growth influenza virus
Lin et al. Analysis of the phylogeny of Chinese H9N2 avian influenza viruses and their pathogenicity in mice
Ahad et al. Zoonosis Update on H9N2 Avian Influenza Virus.
Lei et al. Intranasal immunization of recombinant Lactococcus lactis induces protection against H5N1 virus in ferrets
Horimoto et al. Designing vaccines for pandemic influenza
Su et al. Emergence and pandemic potential of avian influenza a (H7N9) virus
Lee et al. Cell culture-based influenza vaccines as alternatives to egg-based vaccines